Kintor Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Kintor Pharmaceutical's earnings have been declining at an average annual rate of -27.9%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 21.2% per year.
Key information
-27.9%
Earnings growth rate
-19.1%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 21.2% |
| Return on equity | -231.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Nov 16
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Apr 28Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Dec 06Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?
Sep 01Kintor Pharmaceutical Limited (HKG:9939) Insiders Increased Their Holdings
Feb 17What Kind Of Investors Own Most Of Kintor Pharmaceutical Limited (HKG:9939)?
Dec 23
Revenue & Expenses BreakdownBeta
How Kintor Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -1,061 | 96 | 939 |
| 30 Sep 23 | 0 | -854 | 116 | 735 |
| 30 Jun 23 | 0 | -648 | 136 | 532 |
| 31 Mar 23 | 0 | -801 | 144 | 680 |
| 31 Dec 22 | 0 | -954 | 153 | 828 |
| 30 Sep 22 | 17 | -995 | 145 | 887 |
| 30 Jun 22 | 34 | -1,035 | 138 | 947 |
| 31 Mar 22 | 34 | -938 | 128 | 857 |
| 31 Dec 21 | 34 | -842 | 118 | 768 |
| 30 Sep 21 | 17 | -740 | 116 | 615 |
| 30 Jun 21 | 0 | -639 | 114 | 463 |
| 31 Mar 21 | 0 | -573 | 100 | 396 |
| 31 Dec 20 | 0 | -508 | 86 | 329 |
| 30 Sep 20 | 0 | -419 | 63 | 301 |
| 30 Jun 20 | 0 | -330 | 39 | 273 |
| 31 Mar 20 | 0 | -281 | 30 | 243 |
| 31 Dec 19 | 0 | -233 | 21 | 214 |
| 31 Dec 18 | 1 | -108 | 24 | 93 |
| 31 Dec 17 | 0 | -46 | 50 | 0 |
| 30 Sep 17 | 0 | -41 | 44 | 0 |
| 30 Jun 17 | 0 | -35 | 39 | 0 |
| 31 Mar 17 | 1 | -45 | 49 | 0 |
| 31 Dec 16 | 1 | -54 | 60 | 0 |
| 31 Dec 15 | 0 | -11 | 14 | 0 |
Quality Earnings: 9939 is currently unprofitable.
Growing Profit Margin: 9939 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9939 is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.
Accelerating Growth: Unable to compare 9939's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9939 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 9939 has a negative Return on Equity (-231.56%), as it is currently unprofitable.